Form 4 for RGEN REPLIGEN CORP
Accepted 2026-09-22 16:07:23 ET · period of report 2026-09-21 · accession 0001628280-26-063026 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-22 16:07 | 2026-09-21 | RGEN | Loeillot Olivier | CEO, Dir | M - OptEx | $141.79 | +5,426 | 53.8K | +11% | +$769.4K |
| DT | 2026-09-22 16:07 | 2026-09-21 | RGEN | Loeillot Olivier | CEO, Dir | S - Sale+OE | $180.00 | -5,426 | 48.4K | -10% | -$976.7K |
| DT | 2026-09-22 16:07 | 2026-09-21 | RGEN | Loeillot Olivier | CEO, Dir | M - OptEx | $0.00 | -5,426 | 5,426 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-21 | M | A | 5,426 | $141.79 | 53,795 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. |
| 2 | Common | Common Stock | 2026-09-21 | S | D | 5,426 | $180.00 | 48,369 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-09-21 | M | D | 5,426 | $0.00 | 5,426 | D | $141.79 · 2027-09-03 to 2034-09-03 | 5,426 Common Stock | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025. |